Full Text
The Full Text of this article is available as a PDF (871.4 KB).
References
- 1. The GUSTO Investigators : An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682 [DOI] [PubMed] [Google Scholar]
- 2. The GUSTO Angiographic Investigators : The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 3. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO‐I Investigators : Link between the angiographic substudy and mortality outcomes in the large randomized trial of myocardial reperfusion. Circulation 1995; 91: 1923–1928 [DOI] [PubMed] [Google Scholar]
- 4. Ross AM, Coyne K, Moreya E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, Draoui YC, Califf RM, Topol EJ, Van de Werf F, Lundergan CF, for the GUSTO‐I Angiographic Investigators : Extended mortality benefit of early postinfarction reperfusion. Circulation 1998; 97: 1549–1556 [DOI] [PubMed] [Google Scholar]
- 5. Collen D: Thrombolytic therapy. Thromb Haemost 1997; 78 (1): 742–746 [PubMed] [Google Scholar]
- 6. Lefkovits J, Topol EJ: Future directions in thrombolysis for myocardial infarction: What are the unanswered questions? Coron Art Dis 1994; 5: 306–316 [DOI] [PubMed] [Google Scholar]
- 7. Huber K, Maurer G: Thrombolytic therapy in acute myocardial infarction. Sem Thromb Hemost 1996; 22: 15–26 [DOI] [PubMed] [Google Scholar]
- 8. Van de Werf F: TNK‐t‐PA: Results of the phase II trials. TIMI 10B and ASSENT‐1. Presented at the New Developments in Thrombolytic and Antithrombotic Therapy Satellite Symposium at the XIX Congress of the European Society of Cardiology, August 24–28, 1997, Stockholm, Sweden
- 9. Ross AM: New thrombolytic agents. J Intervent Cardiol 1997; 10: 395–399 [Google Scholar]
- 10. Smalling RW: Molecular biology of plasminogen activators: What are the clinical implications of drug design? Am J Cardiol 1996; 78 (suppl 12A): 2–7 [DOI] [PubMed] [Google Scholar]
- 11. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A, and the RAPID Investigators : More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725–2732 [DOI] [PubMed] [Google Scholar]
- 12. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD for the RAPID II Investigators : Randomized comparison of coronary thrombolysis achieved with double‐bolus reteplase (recombinant plasminogen activator) and front‐loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94: 891–898 [DOI] [PubMed] [Google Scholar]
- 13. The GUSTO III Investigators : Comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–1123 [DOI] [PubMed] [Google Scholar]
- 14. White HD: Thrombolytic therapy and equivalence trials. J Am Coll Cardiol 1998; 31: 494–496 [DOI] [PubMed] [Google Scholar]
- 15. Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, Topol EJ for the GUSTO‐III Investigators : Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 1998; 31: 1466–1473 [DOI] [PubMed] [Google Scholar]
- 16. Stringer KA: Biochemical and pharmacologic comparison of thrombolytic agents. Pharmacotherapy 1996; 16 (5 pt. 2) 119S–126S [PubMed] [Google Scholar]
- 17. Koster RW, Cohen AF, Hopkins GR, Beier H, Gunzler WA, van der Wouw PA: Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single‐chain urokinase‐type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994; 72: 740–744 [PubMed] [Google Scholar]
- 18. Cutler D, Bode C, Runge MS: The promise of new genetically engineered plasminogen activators. J Vasc Intervent Radiol 1995; 6: 3S–7S [DOI] [PubMed] [Google Scholar]
- 19. Sasahara AA, Barker WM, Weaver WD, Hartmann J, Anderson JL, Sudhakar Reddy P, Villiard EM: Clinical studies with the new glycosylated recombinant prourokinase. J Vasc Intervent Radiol 1995; 6 (suppl): 84S–93S [DOI] [PubMed] [Google Scholar]
- 20. Spiecker M, Meyer J: Prourokinase für die Infarkttherapie (prourokinase for treatment of acute myocardial infarction). Herz 1994; 19: 326–335 [PubMed] [Google Scholar]
- 21. Vermeer F, Bär F, Windeler J, Schenkel W: Saruplase, a new fibrin specific thrombolytic agent: Final results of the PASS study (1689 patients). Circulation 1993; 88: I–292 [Google Scholar]
- 22. Tebbe U, Windeler J, Boesl I, Hoffmann H, Wojcik J, Ashmawy M, Schwarz ER, von Lewis of Menar P, Rosemeyer P, Hopkins G, Barth H on behalf of the LIMITS Study Group : Thrombolysis with recombinant unglycosylated single‐chain urokinase‐type plasminogen activator (saruplase) in acute myocardial infarction: Influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis with Saruplase. J Am Coll Cardiol 1995; 26: 365–373 [DOI] [PubMed] [Google Scholar]
- 23. Bär FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, Spieker M, Macaya C, Hanssen M, Heras M, Boland JP, Morice M‐C, Dunn FG, Uebis R, Hamm C, Ayzenberg O, Strupp G, Withagen AJ, Klein W, Windeler J, Hopkins G, Barth H, von Fisenne MJM for the SESAM Study Group : Comparison of saruplase and alteplase in acute myocardial infarction. Am J Cardiol 1997; 79: 727–732 [DOI] [PubMed] [Google Scholar]
- 24. PRIMI Trial Study Group : Randomized double‐blind trial of recombinant pro‐urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863–868 [PubMed] [Google Scholar]
- 25. Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins GR, Fennel W, Betriu A, Ruda M, Mlczoch J: Randomized, double‐blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS equivalence trial. J Am Coll Cardiol 1998; 31: 487–493 [DOI] [PubMed] [Google Scholar]
- 26. Bode C, Peter K, Nordt T, Kohler B, Moser M, Ruef J, Runge MS: New developments in thrombolytic therapy. Fibrin Proteol 1997; 11 (suppl 1): 109–114 [Google Scholar]
- 27. Bode C, Runge MS, Schonermark S, Eberle T, Newell JB, Kubler W, Haber E: Conjugation to an antifibrin Fab' enhances fibrinolytic potency of single‐chain urokinase plasminogen activator. Circulation 1990; 81: 1974–1980 [DOI] [PubMed] [Google Scholar]
- 28. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF: A faster‐acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670–3674 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Topol EJ: Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998; 97: 211–218 [DOI] [PubMed] [Google Scholar]
- 30. DeMarco E, Rebuzzi AG, Quaranta G, ven de Greef W, Kol A, Biasucci LG, Maseri A, Andreotti F: Lack of procoagulant effect after TNK‐plasminogen activator in patients with acute myocardial infarction. Eur Heart J 1998; 19 (suppl): 5 [Google Scholar]
- 31. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E, and the TIMI 10A Investigators : TNK‐tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose‐ranging trial. Circulation 1997; 95: 351–356 [DOI] [PubMed] [Google Scholar]
- 32. Cannon CP, McCabe CH, Gibson CM, Adgey AJ, Schweiger MJ, Sequeira RF, Frey M, Mueller HS, McCluskey ER, Fox NL, Van de Werf F, Braunwald E, Weaver WD: TNK‐tissue plasminogen activator compared with front‐loaded tissue plasminogen activator in acute myocardial infarction: Primary results of the TIMI 10B trial. Circulation 1997; 96 (8 I) (suppl ): I–206 [DOI] [PubMed] [Google Scholar]
- 33. Giugliano RP, Cannon CP, McCabe CH, Van de Werf F, Braunwald E: Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: Results from TIMI 10B and ASSENT I. Circulation 1997; 96 (8 I) (suppl ): I–535 [Google Scholar]
- 34. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe C, Raymond L, Fortin T, Poole WK, Braunwald E, for the TIMI 4 Study Group : TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879–888 [DOI] [PubMed] [Google Scholar]
- 35. Gibson CM: A randomized prospective comparison of t‐PA with TNK using the TIMI frame count: Results of TIMI‐10B. Presented at the 70th Scientific Sessions of the American Heart Association; November 9–12, 1997; Orlando, Florida
- 36. Gibson CM, Cannon CP, McCabe C, Van de Werf F, Braunwald E: A randomized prospective comparison of TPA with TNK using the TIMI frame count: Results of TIMI 10B. Circulation 1997; 96 (8 I) (suppl ): I330–I331 [Google Scholar]
- 37. Lerakis S, Stouffer GA, Runge MS: New thrombolytics: What is under development? BioDrugs 1997; 8 (1): 24–32 [Google Scholar]
- 38. Ogata N, Ogata Y, Hokamaki J, Araki H, Morikami Y, Numata Y: Serial changes of plasminogen activator inhibitor activity in thrombolytic therapy for acute myocardial infarction: Comparison between thrombolytic therapies with mutant TPA (lanoteplase/BMS‐200980) and recombinant TPA (alteplase). Circulation 1996; 94 (8 I) (suppl ): I–89 [Google Scholar]
- 39. Thadani U: Lanoteplase: The InTIME Study. Presented at Myocardial Reperfusion X: Concepts and Controversies; Satellite symposium at the 46th Annual Scientific Session of the American College of Cardiology; March 14, 1997; Anaheim, California
- 40. Liao WC, Beierle FA, Stouffer BC, Dockens RC, Abbud ZA, Tay LK, Knaus DM, Raymond RH, Chew PH, Kostis JB: Single bolus regiment of lanoteplase (nPA) in acute myocardial infarction: Pharmacokinetic evaluation from InTime‐I study. Circulation 1997; 96 (8 I) (suppl ): I–260–261 [Google Scholar]
- 41. Lundergan CF, Reiner JS, McCarthy WF, Coyne KS, Califf RM, Ross AM, for the GUSTO‐I Investigators : Clinical predictors of early infarct related artery patency following thrombolytic therapy: Importance of body weight, smoking history, infarct related artery and choice of thrombolytic regimen: The GUSTO‐1 experience. J Am Coll Cardiol 1998: 32 (3); 641–647 [DOI] [PubMed] [Google Scholar]
- 42. Collen D, Stock L, LaCroix H, Suy R, Vanderscheuren S: Recombinant staphylokinase variants with altered immunoreactivity IV: Identification of variants with reduced antibody induction but intact potency. Circulation 1997; 95: 463–472 [DOI] [PubMed] [Google Scholar]
- 43. Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, Van de Werf F, for the STAR Trial group : A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044–2049 [DOI] [PubMed] [Google Scholar]
- 44. Gulba DC, Bode C, Runge MS, Huber K: Thrombolytic agents—an overview. Ann Hematol 1996; 73 (suppl I): S9–S27 [PubMed] [Google Scholar]
- 45. Collen D: Staphylokinase: A potent, uniquely fibrin‐selective thrombolytic agent. Nature Med 1998; 4 (3): 279–284 [DOI] [PubMed] [Google Scholar]
- 46. Collen D, Vanderschueren S, Van de Werf F: Fibrin‐selective thrombolytic therapy with recombinant staphylokinase. Haemostasis 1996; 26 (suppl 4): 294–300 [DOI] [PubMed] [Google Scholar]
- 47. Collen D, Moreau H, Stock L, Vanderscheuren S: Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. Circulation 1996; 94: 207–216 [DOI] [PubMed] [Google Scholar]
- 48. Van de Werf F: New fibrinolytic landscape (TNK, nPA, staphylokinase). Presented at Myocardial Reperfusion XI: Concepts and Controversies; Satellite symposium at the 46th Annual Scientific Session of the American College of Cardiology; March 28, 1998; Atlanta, Georgia
- 49. Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J, Mark GE, Shebuski RJ: Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244–253 [DOI] [PubMed] [Google Scholar]
- 50. Mellott MJ, Stabilito II, Holahan MA, Cuca GC. Wang S, Li P, Barrett JS, Lynch JJ, Gardell SJ: Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992; 12: 212–221 [DOI] [PubMed] [Google Scholar]
- 51. Montoney M, Gardell SJ, Marder VJ: Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540–1544 [DOI] [PubMed] [Google Scholar]
- 52. Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey AJJ, Ghali M, Coussement P, Anderson KM, Scherer J, Van de Werf F, Braunwald E, for the TIMI 14 Investigators : Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 trial. J Am Coll Cardiol 1998; 31 (suppl): 191A [Google Scholar]
- 53. Ross AM: The Plasminogen Activator‐Angioplasty Compatibility Trial (PACT). Presented at Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Satellite symposium at the 70th Scientific Sessions of the American Heart Association; November 8, 1997; Orlando, Florida
- 54. Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K: Improved thrombolysis in acute myocardial infarction with front‐loaded administration of alteplase: Results of the rt‐PA‐APSAC patency study (TAPS). J Am Coll Cardiol 1992; 19: 885–891 [DOI] [PubMed] [Google Scholar]